# US 2020/0138933 A1 · Immunogenic compositions for the prevention and treatment of meningococcal disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138933 A1
- Document ID: US20200138933A1
- Status: Published application
- Kind: A1
- Application number: 16/736,619
- Filed: 2020-01-07
- Published: 2020-05-07
- Earliest claimed: 2001-10-11
- Assignees: Wyeth Holdings Corporation
- Applicants: Wyeth Holdings LLC
- Inventors: Gary W. Zlotnick; Leah D. Fletcher; John E. Farley; Liesel A. Bernfield; Robert J. Zagursky; Benjamin J. Metcalf
- Web page: https://patentgrep.com/patent/US20200138933A1

## CPC

- A61K 39/095: Neisseria
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/22: from Neisseriaceae (F)
- C07K 16/1217: Neisseriaceae (F)
- C12N 9/2417: {from microbiological source}
- C12N 9/2465: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
- C12N 9/2471: {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}
- G01N 33/56911: {Bacteria}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- G01N 2333/22: from Neisseriaceae (F), e.g. Acinetobacter
- Y10S 530/825: Bacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

## Claims

### Claim 1

A composition comprising: (a) at least one protein encoded by an open reading frame of Neisseria species (ORF2086), said open reading frame encoding a crossreactive immunogenic antigen, and said crossreactive immunogenic antigen providing immunogenicity against infection by Neisseria meningitidis serogroup B in a subject; or (b) at least one immunogenic portion of at least one protein described in (a); or (c) at least one biological equivalent of at least one protein described in (a) or immunogenic fragment described in (b), wherein the protein comprises any of the even numbered amino acid sequences of 2-252.

### Claim 2

A composition comprising: at least one polynucleotide that (a) encodes at least one protein encoded by an open reading frame of Neisseria species (ORF2086) or at least one immunogenic portion or biological equivalent of said at least one protein, said open reading frame encoding a crossreactive immunogenic antigen, and said crossreactive immunogenic antigen providing immunogenicity against infection by Neisseria meningitidis serogroup B in a subject; or (b) hybridizes under stringent conditions to any of the polynucleotides described in (a), wherein the protein comprises any of the even numbered amino acid sequences of 2-252.

### Claim 3 (depends on 2)

The composition of claim 2, additionally comprising a P4 leader sequence (SEQ ID NO. 322).

### Claim 4 (depends on 2)

The composition of claim 2, wherein said composition comprises a vector.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the vector is a plasmid.

### Claim 6 (depends on 4)

The composition of claim 4, wherein said at least one polynucleotide comprises the nucleic acid sequence of any of the odd numbered SEQ ID NOS: 1-253.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the stringent conditions are high stringency southern hybridization conditions.

### Claim 8

A method of inducing an immune response against Neisseria meningitidis serogroup B subfamily B in a mammal comprising administering to said mammal a composition comprising an immunologically effective amount of a composition comprising an isolated and purified protein having the amino acid sequence of any one of the even numbered amino acid sequences of 2-252.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the at least one isolated and purified protein is nonpathogenic.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the at least one isolated and purified protein has a molecular weight of 26,000 to 30,000 daltons as measured by mass spectroscopy.

### Claim 11 (depends on 8)

The method according to claim 8, wherein said composition further comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier.

### Claim 12 (depends on 8)

The method according to claim 8, wherein said composition further comprises a carrier.

### Claim 13 (depends on 8)

The method according to claim 8, wherein said composition further an adjuvant.

### Claim 14 (depends on 8)

The method according to claim 8, wherein said adjuvant comprises a liquid.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the at least one isolated and purified protein is a recombinant protein.

### Claim 16 (depends on 8)

The method according to claim 8, wherein the at least one protein is a lipoprotein.

### Claim 17 (depends on 8)

The method according to claim 8, wherein the at least one protein is non-lipidated.

### Claim 18 (depends on 8)

The method according to claim 8, wherein the composition further comprises at least one additional surface antigen of Neisseria species, said additional surface antigen being a non-ORF2086 protein.

### Claim 19 (depends on 8)

The method according to claim 8, wherein said composition further comprises a polysaccharide.

### Claim 20 (depends on 8)

The method according to claim 8, wherein said composition comprises an additional peptide, polypeptide or protein, wherein the at least one isolated and purified protein and the additional peptide, the additional polypeptide or the additional protein form a conjugate.
